Lapatinib in early breast cancer—questions to be resolved

The Lancet Oncology

Volume 14, Issue 1, January 2013, Pages 11-12

J Baselga et al.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Lancet
(2012)
EH Romond et al.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
N Engl J Med
(2005)
NL Spector et al.
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
J Clin Oncol
(2005)
CE Geyer et al.
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
N Engl J Med
(2006)
JE Frampton
Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer
Drugs
(2009)
M Scaltriti et al.
Clinical Benefit of Lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
Clin Cancer Res
(2010)

There are more references available in the full text version of this article.